In 1895, the Association for the Control of Infectious Diseases was created, and in 1896 the Bacteriological Institute was founded in Kyiv. In 1897, a shelter for vaccination of the population was opened opposite the building.
20th century
In 1920, with the opening of epidemiological, microbiological, parasitological and sanitary-hygienic departments, it was renamed "Sanitary and Bacteriological Institute." In 1938, the Institute was divided into two parts: scientific and manufacturing. It was renamed "Ukrainian Institute of Epidemiology and Microbiology." At this time, the staff consisted of 250 employees. During the World War II, the Institute was evacuated to Kuibyshev and continued the research. After the war, manufacturing returned to Kyiv. In 1955, the manufacturing expanded to 12 bacterial drugs. The institute begins to export to Europe, the Middle East, and India.
21st century
In 2005, the company implemented the technology of the virus inactivation by the solvent/detergent method in the production of immunoglobulins. In 2005, at the International Forum of Quality, the enterprise receives the ISO 9001 certificate. In 2009, after a series of changes, reorganizations, and renamings, PrJSC Biopharma was formed. In 2012, Horizon Capital and FMO invested into Biopharma for building a new biopharmaceutical production factory equipped with a quality control laboratory. In 2014, the first phase of the Biopharmaceutical Research and Manufacturing Complex was launched in Bila Tserkva. It includes a pharmaceutical plant for the production of medicines, center for research, development and technology, laboratory building for quality control of drugs, warehouses for raw materials and finished products, housing for power systems. The official opening of the Biopharmaceutical NSC "Biopharma" took place on June 16, 2015. On this occasion, the company handed over medicines worth 1 million UAH, for the needs of the Ministry of Defense and the treatment of military personnel. In September 2018 company joined The European Business Association. 2019 Biopharma jointly with the Ministry of Health of Ukraine held an international forum on blood components and preparations - "Actual issues of industrial production of blood products". Within the framework of the forum, the official opening ceremony of the plasma fractionation plant was held, which became the first such plant in Ukraine and can process up to one million liters of plasma per year.
Construction of a new complex
At the end of 2016, Biopharma started the third stage of the construction – the plant for blood plasma fractionation . In October 2017, after the construction of a new building, the installation of technical equipment was started. At the new facilities, the company will produce Albumin, Bioven, and Immunoglobulin that help treat diseases caused by immunodeficiency. The opening of the new complex took place in summer 2018. Mr. Khmelnytsky and his partners invested $42 million in the research and production facility. 2019 — opening and launch of the first plasma fractionation plant in Ukraine. This technology enables to extract life-saving drugs, requires advanced research and development, GMP-certified equipment and facilities. $75 million was raised to build the plant.
Priorities and social benchmarks
Biopharma is involved in solving the problem of hemophilia and combating the AIDS epidemic and hepatitis C in Ukraine. In 2017, as part of a public-private partnership, Biopharma invested over $3.5 million in the reconstruction and modernization of the Sumy Regional Blood Service Center. It is the first blood center in Ukraine certified according to the international standard ISO 9001: 2015.
